Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Nasus Pharma (NYSE: NSRX) announced on October 8, 2025 expanded agreements with Aptar France and AptarGroup to support development and planned commercialization of NS002, an intranasal powder epinephrine candidate.
The collaboration secures a commercially proven Unit Dose System technology, access to Aptar's manufacturing, supply‑chain and technical expertise, and establishes a framework to support regulatory submissions to the FDA and EMA, aiming to accelerate NS002's path to market and reduce development risk.
Nasus Pharma (NYSE: NSRX) ha annunciato l'8 ottobre 2025 di aver ampliato accordi con Aptar France e AptarGroup per supportare lo sviluppo e la prevista commercializzazione di NS002, un candidato farmacologico intranasale in polvere di epinefrina.
La collaborazione garantisce una tecnologia di Unit Dose System commercialmente consolidata, l'accesso alle attività di produzione, catena di fornitura e competenze tecniche di Aptar, e istituisce un quadro per supportare le sottomissioni regolatorie alla FDA e all'EMA, con l'obiettivo di accelerare il percorso di NS002 verso il mercato e ridurre il rischio di sviluppo.
Nasus Pharma (NYSE: NSRX) anunció el 8 de octubre de 2025 la ampliación de acuerdos con Aptar France y AptarGroup para apoyar el desarrollo y la prevista comercialización de NS002, un candidato de epinefrina en polvo para uso intranasal.
La colaboración garantiza una tecnología de Sistema de Dosis Unitaria comercialmente probada, acceso a la fabricación, cadena de suministro y experiencia técnica de Aptar, y establece un marco para apoyar las presentaciones regulatorias ante la FDA y la EMA, con el objetivo de acelerar el camino de NS002 al mercado y reducir el riesgo de desarrollo.
Nasus Pharma (NYSE: NSRX)는 2025년 10월 8일 Aptar France 및 AptarGroup과의 계약 확장을 발표하여 NS002, 코 비강 내 분말 에피네프린 후보물질의 개발 및 예정된 상용화를 지원합니다.
협력은 상용으로 입증된 단위 용량 시스템(Unit Dose System) 기술에 대한 접근과 Aptar의 제조, 공급망 및 기술 전문성 확보를 보장하며, FDA 및 EMA에 대한 규제 제출을 지원하기 위한 프레임워크를 수립하여 NS002의 시장 진입 경로를 가속하고 개발 리스크를 낮추는 것을 목표로 합니다.
Nasus Pharma (NYSE: NSRX) a annoncé le 8 octobre 2025 l'élargissement des accords avec Aptar France et AptarGroup pour soutenir le développement et la mise sur le marché prévue de NS002, un candidat d'épinéphrine intranasale sous forme de poudre.
La collaboration garantit une technologie de système de dose unitaire commercialement éprouvée, l'accès à la fabrication, à la chaîne d'approvisionnement et à l'expertise technique d'Aptar, et établit un cadre pour soutenir les soumissions réglementaires à la FDA et à la EMA, dans le but d'accélérer le chemin de NS002 vers le marché et de réduire les risques de développement.
Nasus Pharma (NYSE: NSRX) gab am 8. Oktober 2025 bekannt, die Vereinbarungen mit Aptar France und AptarGroup zu erweitern, um die Entwicklung und die geplante Vermarktung von NS002, einem intranasal als Pulverformulierter Epinephrin-Kandidat, zu unterstützen.
Die Zusammenarbeit sichert eine kommerziell bewährte Unit-Dose-System-Technologie, den Zugang zu Aptars Fertigung, Lieferkette und technischer Expertise und schafft einen Rahmen zur Unterstützung regulatorischer Einreichungen bei der FDA und der EMA, mit dem Ziel, NS002s Weg zum Markt zu beschleunigen und das Entwicklungsrisiko zu verringern.
شركة Nasus Pharma (بورصة نيويورك: NSRX) أعلنت في 8 أكتوبر 2025 عن توسيع الاتفاقيات مع Aptar France و AptarGroup لدعم تطوير وترويج NS002 كمرشح للإبينفرين عن طريق الأنف في شكل مسحوق.
تؤمن الشراكة تقنية نظام الجرعة الواحدة المعتمد تجارياً، والوصول إلى تصنيع Aptar وسلسلة التوريد والخبرة الفنية، وتؤسس إطاراً لدعم تقديمات تنظيمية إلى FDA وEMA، بهدف تسريع مسار NS002 إلى السوق وتقليل مخاطر التطوير.
Nasus Pharma (NYSE: NSRX) 于2025年10月8日宣布扩大与 Aptar France 和 AptarGroup 的协议，以支持开发和计划推向市场的 NS002，这是一种用于鼻腔输入的粉末状肾上腺素候选药物。
此次合作确保获得商业验证的单位剂量系统技术、获取 Aptar 的制造、供应链和技术专业知识，并建立一个框架，以支持向 FDA 和 EMA 提交监管申请，旨在加速 NS002 的上市路径并降低开发风险。
- Secured commercially proven Unit Dose System technology
- Access to Aptar manufacturing and supply‑chain capabilities
- Framework to support regulatory submissions to FDA and EMA
- Collaboration intended to accelerate NS002 development to commercialization
- None.
Insights
Nasus secured a manufacturing and regulatory partner to de‑risk NS002 development and support commercialization plans.
Nasus Pharma partnered with Aptar to supply a proven Unit Dose System and end‑to‑end development and manufacturing support for its intranasal epinephrine candidate NS002. This deal links device validation, technical expertise, and supply‑chain capacity directly to ongoing clinical work, which streamlines the path from clinical development to market authorization.
Key dependencies include successful regulatory filings with the FDA and EMA, device validation and manufacturing transfer activities, and completion of required clinical data. Each dependency carries execution risk; regulatory questions, process validation issues, or supply chain delays could slow timelines or increase costs.
Watch for formal regulatory submission milestones, device validation/transfer outcomes, and manufacturing batch release data as they progress from clinical to commercial scale. The agreement announced on
Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructure
TEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup, Inc. (collectively, “Aptar”), a leading global manufacturer of drug delivery systems, to support the ongoing clinical development and planned commercialization of NS002, Nasus Pharma's intranasal powder epinephrine product candidate.
"This collaboration represents a significant milestone for Nasus Pharma and for our NS002 program," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Through this collaboration, Nasus Pharma will secure a commercially proven Unit Dose System technology, providing us with a validated dosing infrastructure. This strategic relationship allows us to benefit from established regulatory pathways, manufacturing capabilities and supply chain, accelerating NS002's path to market while reducing development risks."
The collaboration establishes a comprehensive framework to support the development of NS002 through regulatory submissions with both the U.S. Food and Drug Administration (the “FDA”) and the European Medicines Agency (the “EMA”). This strategic relationship provides Nasus with access to Aptar's technical expertise and manufacturing capabilities to advance NS002 through current clinical development to commercialization in alignment with Nasus Pharma's timeline and objectives.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or Linkedin.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: statements regarding the development and commercialization of NS002; the potential benefits of the collaboration with Aptar; the potential market opportunity for NS002; and that the collaboration with Aptar is accelerating NS002's path to market while reducing development risks. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s prospectus related to filed with the U.S. Securities and Exchange Commission dated August 12, 2025. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com
Investor Contact
Arx Investor Relations
North American Equities Desk
nasus@arxhq.com
FAQ
What did Nasus Pharma announce about NS002 on October 8, 2025 (NSRX)?
How does the Aptar collaboration affect NS002 regulatory filings for NSRX?
What manufacturing benefit does Nasus Pharma gain from the Aptar deal for NSRX?
Will the Aptar agreement speed NS002's path to market for NSRX shareholders?
What specific delivery technology did Nasus secure for NS002 (NSRX)?
